Intra-Arterial Chemotherapy for Retinoblastoma - Risk and Reward: Interview with Patricia Chevez-Barrios, MD, and Mathew Wilson, MD, FACS

American Academy of Ophthalmology Podcasts

Content provided by Eric Soderblom and American Academy of Ophthalmology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Eric Soderblom and American Academy of Ophthalmology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

13y ago 14:16

MP3•Episode home

Archived series ("Inactive feed" status)

When? This feed was archived on October 19, 2022 06:31 (1+ y ago). Last successful fetch was on August 11, 2019 01:09 (4+ y ago)

Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

A conversation between Patricia Chevez-Barrios, MD, and Mathew Wilson, MD, FACS. Since intra-arterial chemotherapy for retinoblastoma reemerged five years ago, the procedure has been performed successfully in more than 25 countries, with high rates of globe salvage. But as the procedure has gained traction, significant complications and unanswered questions have also surfaced. Drs. Matt Wilson and Patricia Chevez-Barrios discuss those questions and the potential risks of treating the eye first rather than the patient. (June 2011)

38 episodes

#AAOS #Ophthalmology #Glaucoma #Cornea #Macula #Retina #Sclera #Cataract #Lasik #Lasek #Uveitis #Oculoplastics #Neuro-ophthalmology #Isrs #Eric Soderblom #Health and Well-Being #American Academy Of Ophthalmology #AMD